Overall Survival for Pembrolizumab in Advanced NSCLC: Edward B. Garon, MD

Non-small cell lung cancer (NSCLC) has traditionally had a poor prognosis in terms of overall survival. This dismal outcome is changing, however: the phase 1 KEYNOTE-001 study found that pembrolizumab (Keytruda®, Merck) substantially increases five-year overall survival for patients with advanced NSCLC. In this interview with i3 Health, Edward B. Garon, MD, the study's lead investigator, discusses the trial's results and their implications for patients and physicians. Can you comment on the sign...
Continue reading

FDA Expands Pembrolizumab Approval for NSCLC

Previously, pembrolizumab (Keytruda®, Merck Inc.) was approved as a single agent for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 with a tumor proportion score (TPS)  greater than or equal to 50%. The FDA has now expanded approval for first-line pembrolizumab to include patients with stage III NSCLC who do not qualify for surgical resection or definitive chemoradiation or metastatic NSCLC. For patients to qualify for tre...
Continue reading

Prophylactic Cranial Irradiation for Locally Advanced NSCLC

Patients with locally advanced non-small cell lung cancer (NSCLC) are at high risk for developing brain metastases. In other cancers that have a propensity to metastasize to the brain, including small cell lung cancer, a treatment called prophylactic cranial irradiation (PCI) is used in order to prevent brain metastases. Now, a phase 3 clinical trial reports that PCI also decreases a patient's chances of developing brain metastasis in NSCLC. In this study, which was published in JAMA Oncology, 3...
Continue reading

Beating Cancer Cells at Their Own Game

For many patients with cancer, treatment resistance develops, leaving cancerous cells to continue to proliferate. Viewing the capability of cancer cells to develop resistance to drugs as a type of evolutionary game, researchers at the Cleveland Clinic developed a game assay using a model of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) cells to measure and explain the interactions between drug-sensitive and drug-resistant cancer cells.  "Rather than searching ...
Continue reading

Semaphorin Contributes to Lung Cancer Treatment Resistance

Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancer (NSCLC) in patients who have epidermal growth factor receptor (EGFR) mutations. However, when patients relapse, they usually develop TKI resistance. Scientists discovered a protein called semaphorin was a piece of the drug-resistance puzzle. In a study published in JCI Insight, researchers revealed a specific semaphorin called Semaphorin 7a (SEMA7A) as a target gene of EGFR mutations that plays a significant role in a...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.